Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit

Ovid Therapeutics Inc., a biopharmaceutical company dedicated to improving the lives of individuals with epilepsies and seizure-related disorders, is set to participate in the Jefferies Inaugural Biotech CNS/Neuro Summit on October 12, 2023. The event, taking place in New York, will provide Ovid Therapeutics with an opportunity to showcase its groundbreaking research and development efforts.

During the summit, Ovid Therapeutics will present its innovative pipeline of targeted small molecule candidates aimed at modulating the factors involved in neuronal hyperexcitation, which can lead to seizures and other neuropathological symptoms. The company’s programs include OV888, a potent and highly selective ROCK2 inhibitor, which shows promise in treating lesions associated with cerebral cavernous malformations. Additionally, OV329, a GABA-aminotransferase inhibitor, is being developed to address treatment-resistant seizures, while OV350, a direct activator of the KCC2 transporter, holds potential for the treatment of epilepsies.

Ovid Therapeutics is also actively involved in the development of soticlestat, a cholesterol 24-hydroxylase inhibitor, in collaboration with Takeda. Soticlestat is currently undergoing Phase 3 trials for the treatment of Dravet and Lennox-Gastaut syndromes. The company maintains a significant financial interest in the future regulatory development and potential commercialization of soticlestat, further highlighting its commitment to advancing treatments for neurological conditions.

By leveraging courageous science, Ovid Therapeutics aims to revolutionize the field of epilepsy and intractable brain disorders. The company’s dedication to research and development, as well as its focus on targeted therapies, positions it as a key player in the biopharmaceutical industry.

Forward-looking statements made by Ovid Therapeutics highlight the potential of its pipeline candidates and the therapeutic opportunities they present. The company’s commitment to achieving its financial objectives and realizing the benefits of its technology and business strategy further demonstrate its determination to make a significant impact in the field of neurology.

Ovid Therapeutics’ participation in the Jefferies Inaugural Biotech CNS/Neuro Summit serves as a testament to its growing presence and influence in the industry. The live webcast of the presentation will provide valuable insights into the company’s groundbreaking research and development efforts, allowing investors and stakeholders to stay informed about its progress.

As Ovid Therapeutics continues to push the boundaries of science and develop innovative treatments, it remains dedicated to transforming the lives of individuals affected by epilepsies and seizure-related disorders. With a robust pipeline and strategic collaborations, the company is well-positioned to make a positive impact on the lives of patients worldwide.